Pain Management

News
Pain Management
November 20, 2018

Self-experienced acute pain refers to the unpleasant sensory and emotional experience related to tissue damage on one's own body. Self-pain perception evokes an increased pain sensitivity and withdrawal urges from the pain-inducing stimulus. Previous studies revealed that vicarious pain could activate the behavioural defence system, which may result in the decrease in self-pain tolerance and increased self-pain intensity and unpleasantness ratings in the observer.

8min read    
News
Pain Management
November 20, 2018

Pain in children with progressive neurodegenerative/chromosomal conditions and impairment in the central nervous system is recurrent, under-recognised and undertreated as little is known about the characterisation, prevalence and management of pain in children suffering from progressive neurologic, metabolic or chromosomal abnormalities and impairment of the central nervous system.

7min read    
News
Pain Management
November 20, 2018

An injury is a significant risk factor for osteoarthritis (OA), a highly prevalent and disabling joint disease. The joint shape is linked to OA, but the interplay of injury and joint form and is not well known their combined role in OA, particularly at the ankle. Therefore, it explored cross-sectional associations between ankle shape and injury in a large community-based cohort.

8min read    
News
Pain Management
November 20, 2018

Total intravenous anaesthesia (TIVA) shows a statistically significant in reducing complications during endoscopic sinus surgery (ESS), an interpretation of a recently executed a double‐blind, randomised, controlled trial. One of the major complications of endoscopic sinus surgery (ESS) is bleeding which can damage visualisation and delay the operation.

7min read    
News
Pain Management
November 19, 2018

The US FDA just passed a sTMS  new device for migraine prevention. In 2014, the neuromodulation device was approved by the FDA and accepted for acute and preventive treatment in 2014 and 2016, respectively the CE mark in Europe. According to the manufacturer, the device is currently the only product, drug or device approved for the acute treatment of a migraine and the prevention of a chronic migraine and episodic.

7min read